EADO/WCM 2025 | Novel approaches in melanoma
Georgina Long
• 3 Apr 2025
Georgina Long, PhD, MBBS, FRACP, FAHMS, University of Sydney, North Sydney, Australia, comments on the future of drug therapies in melanoma, highlighting the potential for neoadjuvant therapies. Prof. Long notes that a significant proportion of patients (40%) will be fine without further treatment, and that novel approaches such as TILs therapy, mRNA vaccines, and T-cell receptor engagers hold promise for targeting the remaining patients who do not respond to checkpoint inhibitors. This interview took place at the 11th World Congress of Melanoma and 21st EADO Congress in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
